Navigation Links
Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
Date:8/24/2011

NEWTOWN SQUARE, Pa., Aug. 24, 2011 /PRNewswire/ -- Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health. The agreement concerns "Azodyl™," a patented, 100% natural, probiotic dietary supplement indicated for the reduction of azotemia in dogs and cats with moderate to severe renal failure. Developed by Kibow, Azodyl™ has been successfully marketed and sold mainly in USA and Canada since July 2006.

Kibow intends to utilize a major portion of the $2.4 million funding secured for testing a similar, patented, probiotic dietary supplement intended for human consumption. This flagship product, known as "Kibow Biotics™," is targeted towards kidney health and helps improve the quality of life in chronic kidney failure (CKF) patients who also adhere to their routine standardized care of treatment for their pre-existing medical conditions.

Kibow's human clinical trials, involving dialysis and pre-dialysis patients, have already been initiated at Thomas Jefferson University, Philadelphia, PA and at Downstate Medical Center/Kings County Hospitals, State University of New York (SUNY), Brooklyn, NY. Another trial, to be conducted at Mayo clinic, Rochester, MN is soon to begin.

About kidney failure in companion animals:

A leading cause of death among geriatric cats and dogs, "kidney failure" or "renal failure" refers to persistent azotemia, a build-up of uremic toxins in the blood, usually caused by a loss of nephron function in the kidneys.

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission to find a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow(R) Biotics," an orally consumable, enteric-coated gel cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

For more information: Dr. N. Ranganathan, Ph.D., Phone: 610 353-5130, http://www.kibowbiotech.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
2. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
3. Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
4. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
5. Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease
6. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
7. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
8. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
9. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):